Haris Ali, MD, discusses the results of a study evaluating peri-transplant ruxolitinib in patients with myelofibrosis.
Haris Ali, MD, a hematologist/oncologist and associate clinical professor, Department of Hematology & Hematopoietic Cell Transplantation at City of Hope Comprehensive Cancer Center, discusses the results of a study evaluating peri-transplant ruxolitinib in patients with myelofibrosis.
The pilot study aimed to assess the safety and efficacy of the per-transplant ruxolitinib strategy. In terms of safe, Ali says that strategy was well-tolerated, with most of the toxicities being grade 1 in severity. Few patients experienced grade 2 or 3 toxicities, which included renal failure and cardiac arrest in 2 patients. These events were not related to ruxolitinib, Ali explains.
Results also showed that the incidence of high-grade graft-versus-host disease was low in this study. These findings confirm the original hypothesis of the study.
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More